

# Antiviral prophylaxis: herpes simplex virus type 1, herpes simplex virus type 2, varicella zoster virus

Recommendations from the society for diagnosis and therapy of haematological and oncological diseases

---

## **Publisher**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.

Bauhofstr. 12  
D-10117 Berlin

Executive chairwoman: Prof. Dr. med. Claudia Baldus

Phone: +49 (0)30 27 87 60 89 - 0

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Contact person**

Prof. Dr. med. Bernhard Wörmann  
Medical superintendent

## **Source**

[www.onkopedia-guidelines.info](http://www.onkopedia-guidelines.info)

The information of the DGHO Onkopedia Web Site is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the web site is done so for solely educational purposes. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the DGHO Web Site. This includes any implied warranties and conditions that may be derived from the aforementioned web site information.

# Table of contents

<b>1 Summary</b> .....	<b>2</b>
<b>2 Background</b> .....	<b>2</b>
<b>3 Pathogenesis</b> .....	<b>3</b>
<b>4 Clinical presentation</b> .....	<b>3</b>
<b>5 Diagnostic tests</b> .....	<b>3</b>
5.1 Diagnostic tests for herpes viruses.....	3
<b>6 Antiviral prophylaxis against reactivation of herpes viruses ...</b> <b>in patients with solid tumors and hematologic neoplasms</b> <b>(patients with stem cell transplantation and cellular</b> <b>therapy not included here)</b>	<b>4</b>
<b>9 References</b> .....	<b>5</b>
<b>15 Authors' Affiliations</b> .....	<b>6</b>
<b>16 Disclosure of Potential Conflicts of Interest</b> .....	<b>7</b>

# Antiviral prophylaxis: herpes simplex virus type 1, herpes simplex virus type 2, varicella zoster virus

**Date of document:** January 2023

**Compliance rules:**

- [Guideline](#)
- [Conflict of interests](#)

**Authors:** Larissa Henze, Christoph Buhl, Michael Sandherr, Oliver A. Cornely, Werner Heinz, Yascha Khodamoradi, Til Ramón Kiderlen, Philipp Köhler, Alrun Seidler, Rosanne Sprute, Martin Schmidt-Hieber, Marie von Lilienfeld-Toal

for the Working Group on Infections (AGIHO) of the DGHO

**Previous authors:** Lena Maria Biehl, Marcus Hentrich, Gero Massenkeil, Silke Neumann, Olaf Penack

for the Working Group on Infections (AGIHO) of the DGHO

## 1 Summary

Reactivation of viral disease is a major complication of antineoplastic therapy in patients (pat.) with solid tumors or hematologic malignancies. Human herpesviruses (herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus-6 (HHV-6)) and hepatitis viruses (hepatitis B, hepatitis C, hepatitis E) are relevant in this regard due to persistence or chronic infection. Incidence and severity of viral disease depends primarily on the degree of cellular immunosuppression. Targeted drug prophylaxis can be an effective strategy to prevent symptomatic viral reactivation.

The guideline "Management of herpesvirus reactivations in patients with solid tumors and hematologic malignancies" was developed by the Working Group on Infections of the DGHO (AGIHO) for the diagnosis, prophylaxis and therapy of these patients [1]. It is based on a systematic literature search, a uniform assessment of the strength of evidence, and a consensus-building process.

This is a summary of the most important recommendations for antiviral prophylaxis for patients in hematology and oncology who are not undergoing cellular therapy (autologous or allogeneic stem cell transplantation, CAR T-cell therapy) but are being treated with conventionally dosed chemotherapy or monoclonal antibodies or specific inhibitors. This version supplements and updates the current version [2]. Evidence criteria are presented in Onkopedia in the chapter "Infections in the outpatient cancer care".

## 2 Background

Most clinical manifestations of viral diseases result from reactivation of latent infections. The risk of disease by reactivation increases with intensity and duration of T-cell suppression.

The most common pathogens are herpes simplex viruses (HSV-1 and HSV-2), varicella zoster virus (VZV) and hepatitis B virus (HBV). Reactivation of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) plays a minor role outside of allogeneic stem cell transplantation.

However, the importance of viral infections of the respiratory tract has been increasingly recognized in recent years. These are mostly exogenously acquired primary infections. They are associated with an increased rate of secondary complications such as bacterial pneumonia with significant morbidity and mortality.

### 3 Pathogenesis

Human herpesviruses persist after primary infection throughout life. Reactivation can occur in the presence of immunosuppression or other trigger factors and lead to local or systemic disease.

Reactivation of HSV-1, HSV-2 and VZV is relatively common in patients with solid tumors or hematologic neoplasms or during therapy. A comparable risk exists for the reactivation of HBV in patients who have been infected before and show persistence of viral replication.

The risk of viral reactivation depends on the type of malignancy, tumor therapy, and individual factors such as age, comorbidity, comedication, remission status and prior therapy.

### 4 Clinical presentation

Reactivation of HSV-1, HSV-2 may be asymptomatic. Most symptomatic reactivations are herpes labialis, herpes stomatitis and herpes genitalis.

Reactivation of VZV usually results in the clinical picture of shingles (herpes zoster). Depending on the severity of immunosuppression, this can affect several dermatomes or may be disseminated.

HSV-1, HSV-2, and VZV reactivation during severe immunosuppression may be accompanied by organ manifestations associated with high morbidity and mortality. An overview is given in [Table 1](#).

**Table 1: Clinical presentation of reactivation of HSV-1, HSV-2, VZV.**

	HSV-1	HSV-2	VZV
<b>Reactivation</b>	asymptomatic Herpes labialis Stomatitis <sup>1</sup> Herpes genitalis Esophagitis <sup>1</sup> Hepatitis <sup>1</sup> Colitis <sup>1</sup> Pneumonitis <sup>1</sup> Encephalitis Keratitis	asymptomatic Herpes genitalis Hepatitis <sup>1</sup> Meningitis Encephalitis	Herpes zoster Zoster sine herpette (visceral herpes zoster) Herpes zoster, disseminated <sup>1</sup> Hepatitis <sup>1</sup> Pancreatitis <sup>1</sup> Pneumonitis <sup>1</sup> Meningoencephalitis Cerebral vasculopathy Keratitis, uveitis, retinitis

Legend:

<sup>1</sup> in immunocompromised patients

### 5 Diagnostic tests

#### 5.1 Diagnostic tests for herpes viruses

Serologic testing for HSV or VZV (HSV IgG or VZV IgG) can confirm a previous infection. Since the current seroprevalence in adults is about 90% due to high rates of primary infection in childhood (partly asymptomatic) antiviral prophylaxis is adequate for most patients in the given indication as protection against reactivation - even without prior serological testing.

There is no indication for regular screening with PCR for reactivation by HSV-1, HSV-2 or VZV.

## 6 Antiviral prophylaxis against reactivation of herpes viruses in patients with solid tumors and hematologic neoplasms (patients with stem cell transplantation and cellular therapy not included here)

The indications for antiviral pharmacological prophylaxis in patients with solid tumors and hematologic neoplasms are summarized in [Figure 1](#) (regarding HSV-1 and HSV-2) and in [Figure 2](#) (regarding VZV).

The strength of recommendation (SoR) and quality of evidence (QoE) is described in [Table 2](#).

Recommendations for antiviral prophylaxis are based on the risk for symptomatic viral reactivations.

Although vaccination is available for the prevention of VZV reactivation (Shingrix®), the evidence is still insufficient to stop prophylaxis in patients at higher risk.

Aciclovir is commonly used and has been best studied for antiviral pharmacological prophylaxis. The dosages that have been used are inconsistent.

For prophylaxis of reactivations of HSV-1 and HSV-2 aciclovir is usually given at a dose of 400 mg orally twice daily.

For prophylaxis of VZV reactivation, dosages of 400 mg orally daily to thrice daily are used.

Evidence for valaciclovir from studies is limited; in clinical practice, it is used in doses of 250 mg or 500 mg orally twice daily for antiviral prophylaxis.

For both drugs, maximum doses must be calculated depending on renal function.


**Table 2: Evidence for pharmacological prophylaxis against reactivation of HSV-1, HSV-2, and VZV.**

Indication	Virus	SoR	QoE	Comment
<b>Solid tumor</b>	HSV-1, HSV-2	D	III	
<i>Exception may be:</i> head and neck tumor and radiochemotherapy	HSV-1, HSV-2	C	IIr	
<b>Solid tumor</b>	VZV	D	III	
<i>Exception may be:</i> prednisolone equivalent > 10 mg daily, for > 14 days	VZV	C	IIu	
<b>AML, ALL; intensive chemotherapy</b>	HSV-1, HSV-2 VZV	B B	I, IIr IIr	
<b>MPN MPN; ruxolitinib</b>	HSV-1, HSV-2 VZV	C B	IIu IIru	
<b>Lymphoma, CLL; immunochemotherapy</b>	HSV-1, HSV-2, VZV	B	IIu	individual risk assessment
<b>Lymphoma, CLL; idelalisib</b>	HSV-1, HSV-2, VZV	B	III	( <a href="#">Figure 1</a> and <a href="#">2</a> )
<b>Lymphoma, CLL; BTK/BCL2 inhibitors</b>	VZV	C	III	advanced therapy
<b>Multiple Myeloma</b>	HSV-1, HSV-2	*	*	
<b>Multiple Myeloma; proteasome inhibitors</b>	VZV	A	IIu	
<b>Multiple Myeloma; lenalidomide, anti-CD38-Ab</b>	VZV	C	IIr	

Legend:

\* assessment difficult, as aciclovir has been used widely in patients treated with proteasome inhibitors as pharmacological prophylaxis against reactivation of VZV

**Figure 1: Indications for drug prophylaxis against HSV-1 and HSV-2 reactivation**



Legend:


<sup>1</sup> exception may be: head and neck tumor treated with radiochemotherapy.

<sup>2</sup> risk factors: aged > 60 years, cumulative prednisolone equivalent > 2500 mg/m<sup>2</sup> BSA, > 1st line of therapy, therapy with bendamustine, maintenance therapy with anti-CD20 antibody, history of febrile neutropenia or HSV/VZV reactivation

<sup>3</sup> mandatory antiviral prophylaxis against CMV reactivation

<sup>4</sup> assessment difficult, as aciclovir has been used widely in patients treated with proteasome inhibitors as pharmacological prophylaxis against reactivation of VZV

**Figure 2: Antiviral prophylaxis against reactivation of VZV (herpes zoster primarily)**



Legend:

<sup>1</sup> exception may be: prednisolone equivalent > 10 mg daily for longer than 14 days.

<sup>2</sup> risk factors: aged > 60 years, cumulative prednisolone equivalent > 2500 mg/m<sup>2</sup> BSA, > 1st line of therapy, therapy with bendamustine, maintenance therapy with anti-CD20 antibody, history of febrile neutropenia or HSV/VZV reactivation

<sup>3</sup> mandatory antiviral prophylaxis against CMV reactivation.

<sup>4</sup> risk factors: ≥ 2nd line of therapy, prior treatment with steroids, history of VZV reactivation, CD4 count < 200/ul

## 9 References

1. Henze L, Buhl C, Sandherr M et al. (2022) Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. Ann Hematol 101(3): 491-511. DOI:10.1007/s00277-021-04746-y.
2. Sandherr M et al: Antiviral prophylaxis in patients with solid tumours and haematological malignancies - Update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 2015 94(9): 1441-50. DOI:10.1007/s00277-015-2447-3.

## 15 Authors' Affiliations

**Dr. med. Christoph Buhl**

Klinikum Leverkusen  
Medizinische Klinik 3  
Am Gesundheitspark 11  
51375 Leverkusen  
[christoph.buhl@klinikum-lev.de](mailto:christoph.buhl@klinikum-lev.de)

**Prof. Dr. med. Oliver A. Cornely**

Uniklinik Köln, Klinik I für Innere Med.  
Zentrum für Klinische Studien  
Infektiologie-Hämatologie-Onkologie  
Kerpener Str. 62  
50937 Köln  
[oliver.cornely@uk-koeln.de](mailto:oliver.cornely@uk-koeln.de)

**Prof. Dr. med. Werner Heinz**

Caritas-Krankenhaus Bad Mergentheim  
Med. Klinik 2  
Umlandstr. 7  
97980 Bad Mergentheim  
[Werner.Heinz@ckbm.de](mailto:Werner.Heinz@ckbm.de)

**Dr. med. Larissa Henze**

Asklepios Harzlinik Goslar  
Medizinische Klinik II  
Hämatologie, Onkologie und Palliativmedizin  
Kösliner Str. 12  
38642 Goslar  
[l.henze@asklepios.com](mailto:l.henze@asklepios.com)

**Dr. med. Yascha Khodamoradi**

**Dr. med. Til Ramón Kiderlen**

Vivantes Auguste-Viktoria-Klinikum  
Rubensstr. 125  
12157 Berlin  
[tilramon.kiderlen@vivantes.de](mailto:tilramon.kiderlen@vivantes.de)

**PD Dr. med. Philipp Köhler**

Universitätsklinikum Köln  
Klinik I für Innere Medizin  
Kerpener Str. 62  
50937 Köln  
[philipp.koehler@uk-koeln.de](mailto:philipp.koehler@uk-koeln.de)

**PD Dr. med. Michael Sandherr**

Deutsche Gesellschaft für Hämatologie  
und Medizinische Onkologie (DGHO)  
Onkopedia-Koordinator  
Bauhofstr. 12  
10117 Berlin  
[sandherr@dgho.de](mailto:sandherr@dgho.de)

**Prof. Dr. med. Martin Schmidt-Hieber**

Medizinische Universität Lausitz - Carl Thiem  
2. Med. Klinik  
Klinik für Hämatologie und Onkologie  
Thiemstr. 111  
03048 Cottbus  
[M.Schmidt\\_Hieber@mul-ct.de](mailto:M.Schmidt_Hieber@mul-ct.de)

**Dr. med. Alrun Seidler**

Städtisches Klinikum München  
Dept. für Mikrobiologie und  
technische Hygiene  
Kölner Platz 1  
80804 München

**Rosanne Sprute**

Uniklinik Köln  
Klinik I für Innere Medizin  
Klinische Infektiologie  
50931 Köln  
[rosanne.sprute@uk-koeln.de](mailto:rosanne.sprute@uk-koeln.de)

**Prof. Dr. med. Marie von Lilienfeld-Toal**

Ruhr-Universität Bochum  
Institut für Diversitätsmedizin  
Universitätsstr. 150  
44801 Bochum  
[marie.vonlilienfeld-toal@ruhr-uni-bochum.de](mailto:marie.vonlilienfeld-toal@ruhr-uni-bochum.de)

## **16 Disclosure of Potential Conflicts of Interest**

according to the [rules of DGHO, OeGHO, SGH+SSH, SGMO](#)

<b>Author</b>	<b>Employer<sup>1</sup></b>	<b>Consulting / Expert opinion<sup>2</sup></b>	<b>Shares / Funds<sup>3</sup></b>	<b>Patent / Copyright / License<sup>4</sup></b>	<b>Fees<sup>5</sup></b>	<b>Funding of scientific research<sup>6</sup></b>	<b>Other financial relations<sup>7</sup></b>	<b>Personal relationship with authorized representatives<sup>8</sup></b>
Buhl, Christoph		<b>No</b>	<b>No</b>	<b>No</b>	<b>No</b>	<b>No</b>	<b>No</b>	<b>No</b>
Cornely, Oliver A.	Uniklinik Köln Kerpener Str. 62 50937 Köln	<b>Yes</b> Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pardes, Pfizer, PSI, Scynexis, Seres; Cidara	<b>Yes</b> CoRe Consulting, EasyRadiology	<b>Yes</b> German Patent and Trade Mark Office (DE 10 2021 113 007.7)	<b>Yes</b> Abbott, Abbvie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana/United Medical/Knight, Hikma, Medscape, MedUpdate, Merck/MSD, Mylan, Noscendo, Pfizer, Shionogi	<b>Yes</b> Amplix, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis	<b>No</b>	<b>No</b>
Heinz, Werner	seit 2021 Caritas Krankenhaus Bad Mergentheim, bis 2020 Klinikum Nordoberpfalz AG, Weiden i.Opf.	<b>Yes</b> Teilnahme an Advisory Board; Abbvie, Amgen, AstraZeneca, Celgene/BMS, Gilead science, Sanofi-Aventis,	<b>No</b>	<b>No</b>	<b>Yes</b> Vortragstätigkeit für Abbvie, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Janssen,	<b>No</b>	<b>Yes</b> Kongress/ Reiseunterstützung durch Abbvie, Astellas, BMS, Ipsen, Novartis	<b>No</b>
Henze, Larissa	seit 04/2022 Asklepios Harzlinien GmbH 07/2015 bis 03/2022 Universitätsmedizin Rostock	<b>No</b>	<b>No</b>	<b>No</b>	<b>No</b>	<b>Yes</b> Bundesministerium für Bildung und Forschung	<b>No</b>	<b>No</b>
Khodamoradi, Yascha	Klinikum der Goethe-Universität Frankfurt	<b>Yes</b> Advisory Board: Gilead Sciences, MSD, ViiV Healthcare, Ferring	<b>No</b>	<b>No</b>	<b>Yes</b> MSD, Elsevier	<b>No</b>	<b>No</b>	<b>No</b>
Kiderlen, Til Ramón	Conflict of interest declarations pending							
Köhler, Philipp	Uniklinik Köln, Klinik I für Innere Medizin	<b>No</b>	<b>No</b>	<b>No</b>	<b>No</b>	<b>No</b>	<b>No</b>	<b>No</b>

Author	Employer <sup>1</sup>	Consulting / Expert opinion <sup>2</sup>	Shares / Funds <sup>3</sup>	Patent / Copy-right / License <sup>4</sup>	Fees <sup>5</sup>	Funding of scientific research <sup>6</sup>	Other financial relations <sup>7</sup>	Personal relationship with authorized representatives <sup>8</sup>
Sandherr, Michael	MVZ Penzberg, Ärztlicher Leiter	<b>Yes</b> Roche, Novartis, BMS, BeiGene	<b>No</b>	<b>No</b>	<b>Yes</b> Roche, Novartis, BMS, GSK, Astra Zeneca	<b>No</b>	<b>No</b>	<b>No</b>
Schmidt-Hieber, Martin	CTK Cottbus	<b>Yes</b> Celgene GmbH, Amgen GmbH, Kite/Pharma Gilead, Sanofi-Aventis Deutschland GmbH, Glaxo Smith Kline GmbH & Co. KG, Bristol Myers Squibb GmbH & Co. KG, Shionogi GmbH, Stemline Therapeutics (keine persönlichen Zuwendungen)	<b>No</b>	<b>No</b>	<b>No</b>	<b>Yes</b> klinische Studien	<b>Yes</b> finanzielle Unterstützung bei der Ausrichtung von Veranstaltungen am Carl-Thiem-Klinikum: Janssen-Cilag GmbH, Takeda Pharma Vertrieb GmbH & Co. KG, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG, Vifor Pharma Deutschland GmbH, Celgene GmbH (keine persönlichen Zuwendungen)	<b>No</b>
Seidler, Al-run	Conflict of interest declarations pending							
Sprute, Rosanne	Uniklinik Köln	<b>No</b>	<b>No</b>	<b>No</b>	<b>Yes</b> Pfizer	<b>No</b>	<b>No</b>	<b>No</b>
von Lilienfeld-Toal, Marie	Universitätsklinikum Jena Leibniz-Institut für Naturstoff Forschung und Infektionsbiologie, Jena	<b>Yes</b> Celgene, Gilead, Oncoceptides, MSD, 4DPharma, Janssen, Shionogi, Pfizer	<b>No</b>	<b>No</b>	<b>Yes</b> Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncoceptides, Merck, CDDF, abbvie, AstraZeneca, Pfizer, Thermofisher, GSK, CDDF	<b>Yes</b> BMBF, Deutsche Jose Carreras Leukämie-Stiftung, IZKF Jena, DFG, Novartis, Gilead, Deutsche Krebshilfe, Celgene, Oncoceptides	<b>Yes</b> Janssen, Celgene	<b>No</b>

Legend:

<sup>1</sup> - Current employer, relevant previous employers in the last 3 years (institution/location).

<sup>2</sup> - Activity as a consultant or expert or paid participation in a scientific advisory board of a company in the health care

*industry (e.g., pharmaceutical industry, medical device industry), a commercially oriented contract research organization, or an insurance company.*

<sup>3</sup> - *Ownership of business shares, stocks, funds with participation of companies of the health care industry.*

<sup>4</sup> - *Relates to drugs and medical devices.*

<sup>5</sup> - *Honoraria for lecturing and training activities or paid authors or co-authorships on behalf of a company in the health care industry, a commercially oriented contracting institute or an insurance company.*

<sup>6</sup> - *Financial support (third-party funds) for research projects or direct financing of employees of the institution by a company in the health care industry, a commercially oriented contract institute or an insurance company.*

<sup>7</sup> - *Other financial relationships, e.g., gifts, travel reimbursements, or other payments in excess of 100 euros outside of research projects, if paid by an entity that has an investment in, license to, or other commercial interest in the subject matter of the investigation.*

<sup>8</sup> - *Personal relationship with an authorized representative(s) of a healthcare company.*